Iloprost therapy acutely decreases oxidative stress in patients affected by systemic sclerosis.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical and Experimental Rheumatology

• Publication date

  2008-11-01

• Fields of study

  Medicine

• Identifiers
  PMID 19210877
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Iloprost infusion does not reduce oxidative stress in systemic sclerosis

  2008cited by this paper
• Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group.

  2007cited by this paper
• Antioxidant status after iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis

  2007cited by this paper
• Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.

  2006cited by this paper
• Effects of iloprost on visual evoked potentials and brain tissue oxidative stress after bilateral common carotid artery occlusion.

  2006cited by this paper
• Possible role of iloprost (stable analog of PG12) in promoting neoangiogenesis in systemic sclerosis.

  2006cited by this paper
• Isoprostanes: markers and mediators of oxidative stress

  2004cited by this paper
• Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: effect of cold exposure.

  2002cited by this paper
• Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway.

  2001cited by this paper
• Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders.

  2001cited by this paper
• 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases.

  1998cited by this paper
• The isoprostanes: unique bioactive products of lipid peroxidation. An overview.

  1998cited by this paper
• The Isoprostanes: Unique Bioactive Products of Lipid Peroxidation

  1997cited by this paper
• Scleroderma Autoantigens Are Uniquely Fragmented by Metal-catalyzed Oxidation Reactions: Implications for Pathogenesis

  1997cited by this paper
• Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma.

  1996cited by this paper
• Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma.

  1996cited by this paper
• Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis.

  1994cited by this paper
• A radical proposal for the pathogenesis of scleroderma.

  1993cited by this paper
• Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

  1988cited by this paper

• Iloprost, a Prostacyclin Analogue, Alleviates Oxidative Stress and Improves Development of Parthenogenetic Porcine Embryos via Nrf2/Keap1 Signaling

  2025cites this paper
• Urinary total superoxide dismutase activity is low in rheumatoid patients, and its low levels are associated with higher DAS28 scores.

  2025cites this paper
• Evaluation of thiol/disulfide homeostasis in rheumatoid arthritis and disease activity.

  2022cites this paper
• Iloprost Attenuates Oxidative Stress-Dependent Activation of Collagen Synthesis Induced by Sera from Scleroderma Patients in Human Pulmonary Microvascular Endothelial Cells

  2021cites this paper
• Oxidative Stress Biomarkers and Peripheral Endothelial Dysfunction in Rheumatoid Arthritis: A Monocentric Cross-Sectional Case-Control Study

  2020cites this paper
• Isoprostane in systemic sclerosis: A systematic review and meta-analysis

  2019cites this paper
• Association Between Exposure to Heavy Metals and Systemic Sclerosis: the Levels of Al, Cd, Hg, and Pb in Blood and Urine of Patients

  2018cites this paper
• The Role of Oxidative Stress in the Development of Systemic Sclerosis Related Vasculopathy

  2018cites this paper
• Points to consider in renal involvement in systemic sclerosis

  2017cites this paper
• The Effect of Oxidative Stress on Pulmonary Involvement in Patients with Systemic Sclerosis

  2015cites this paper
• Evaluating digital vascular perfusion and platelet dysfunction in Raynaud's phenomenon and systemic sclerosis

  2014cites this paper
• Role of Cellular Senescence and NOX4-Mediated Oxidative Stress in Systemic Sclerosis Pathogenesis

  2014cites this paper
• Animal models of systemic sclerosis: their utility and limitations

  2014cites this paper
• Role of Oxidative Stress and Reactive Oxygen Radicals in the Pathogenesis of Systemic Sclerosis

  2013cites this paper
• Long-termcyclicintravenousiloprost insystemicsclerosis: clinicalexperiencefromasinglecenter

  2012cites this paper
• Long-term cyclic intravenous iloprost in systemic sclerosis: clinical experience from a single center.

  2012cites this paper
• Paradoxical Reaction of Raynaud Phenomenon following the Repeated Administration of Lloprost in a Patient with Diffuse Cutaneous Systemic Sclerosis

  2012cites this paper
• Antioxidant effect of Iloprost: current knowledge and therapeutic implications for systemic sclerosis.

  2011cites this paper
• Unauthorized reproduc Re-evaluation of biologic therapies in systemic lupus erythematosus

  2010cites this paper
• Defining the neutrophil phenotype in systemic sclerosis

  2010cites this paper